Werewolf Therapeutics Files 8-K
Ticker: HOWL · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1785530
| Field | Detail |
|---|---|
| Company | Werewolf Therapeutics, Inc. (HOWL) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Werewolf Therapeutics filed an 8-K, likely with financial updates and other disclosures.
AI Summary
On June 25, 2024, Werewolf Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Werewolf Therapeutics is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific negative or positive material information that would immediately alter risk perception.
Key Players & Entities
- Werewolf Therapeutics, Inc. (company) — Registrant
- June 25, 2024 (date) — Date of earliest event reported
- 001-40366 (company) — Commission File Number
- 82-3523180 (company) — IRS Employer Identification No.
- 200 Talcott Ave, 2nd Floor (company) — Principal Executive Offices Address
- Watertown, Massachusetts (company) — Principal Executive Offices Location
- 02472 (company) — Principal Executive Offices Zip Code
- 617-952-0555 (company) — Registrant's telephone number
FAQ
What specific events are being disclosed in this 8-K filing?
The filing indicates disclosures related to 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on June 25, 2024.
What is the Commission File Number for Werewolf Therapeutics, Inc.?
The Commission File Number is 001-40366.
Where are Werewolf Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472.
What is the Standard Industrial Classification code for Werewolf Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,467 words · 6 min read · ~5 pages · Grade level 13.8 · Accepted 2024-06-25 07:07:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share HOWL The Nasdaq
Filing Documents
- d857404d8k.htm (8-K) — 37KB
- d857404dex991.htm (EX-99.1) — 23KB
- g857404g0625015152649.jpg (GRAPHIC) — 4KB
- 0001193125-24-167467.txt ( ) — 199KB
- howl-20240625.xsd (EX-101.SCH) — 2KB
- howl-20240625_lab.xml (EX-101.LAB) — 18KB
- howl-20240625_pre.xml (EX-101.PRE) — 11KB
- d857404d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements Any statements in this Current Report on Form 8-K about the Company's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to substantial risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include statements regarding the Company's strategy, future operations, prospects, plans, objectives of management, the expected timeline regarding the clinical development of product candidates, including the announcement of data, the potential activity and efficacy of product candidates in preclinical studies and clinical trials, and the timing and outcome of planned meetings with regulatory authorities. The words "aim," "anticipate," "approach," "believe," "contemplate," "continue," "could," "design," "designed to," "engineered," "estimate," "expect," "goal," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "promise," "should," "target," "will," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking s
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEREWOLF THERAPEUTICS, INC. By: Date: June 25, 2024 /s/ Timothy W. Trost Timothy W. Trost Chief Financial Officer and Treasurer